Literature DB >> 9296425

Optimal dose of granisetron for prophylaxis against postoperative emesis after gynecological surgery.

K Mikawa1, Y Takao, K Nishina, M Shiga, N Maekawa, H Obara.   

Abstract

UNLABELLED: We previously reported that 20 and 40 microg/kg of granisetron given during anesthesia prevented postoperative emesis with no severe complications. The aim of the current study was to determine the optimal dose of granisetron for the prevention of postoperative nausea and vomiting (PONV) after gynecological surgery. Two hundred female patients (ASA physical status I) were randomly allocated to one of five groups (n = 40 for each): saline (as a control), granisetron 2 microg/kg, granisetron 5 microg/kg, granisetron 10 microg/kg, and granisetron 20 microg/kg. Saline or granisetron was given intravenously immediately after induction of anesthesia. PONV was assessed 24 h after surgery. The percentage of emesis-free patients was significantly greater in the 5- to 20-microg/kg granisetron groups than in the control and 2-microg/kg granisetron groups (18%, 23%, 68%, 78%, and 75% of patients receiving saline or granisetron 2 microg/kg, 5 microg/kg, 10 microg/kg, and 20 microg/kg, respectively). Granisetron doses of 5 microg/kg or larger were also superior to the saline and 2-microg/kg granisetron treatment for the prevention of nausea over the 24-h study period (nausea visual analog scales 24 h after surgery: 49, 41, 18, 16, and 14 mm in the control and granisetron 2 microg/kg, 5 microg/kg, 10 microg/kg, and 20 microg/kg groups, respectively). A smaller proportion of patients received "rescue" antiemetic in the 5-microg/kg or larger granisetron groups than in the control and 2-microg/kg granisetron groups (48%, 40%, 18%, 13%, and 10% of patients in the control and granisetron 2 microg/kg, 5 microg/kg, 10 microg/kg, and 20 microg/kg groups, respectively). The antiemetic effect of granisetron was similar among the groups who received 5-microg/kg or larger doses. In conclusion, we suggest that the optimal dose of granisetron is 5 microg/kg for the prevention of PONV after gynecological surgery. IMPLICATIONS: Nausea and vomiting postoperatively after gynecologic surgery is a significant problem. The authors found that granisetron, a selective antagonist of serotonin, markedly decreases the incidence of postoperative nausea and vomiting at doses of 5 microg/kg or larger.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9296425     DOI: 10.1097/00000539-199709000-00030

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

Review 1.  Dexmedetomidine for antiemesis in gynecologic surgery: a meta-analysis of randomized controlled trials.

Authors:  Wei-Guo Zhong; Xin-Yu Ge; Hai Zhu; Xiao Liang; Hong-Xia Gong; Ming Zhong; Xiang Xiao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.

Authors:  Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke
Journal:  Cochrane Database Syst Rev       Date:  2020-10-19

Review 4.  Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis.

Authors:  Andrea C Tricco; Charlene Soobiah; Erik Blondal; Areti A Veroniki; Paul A Khan; Afshin Vafaei; John Ivory; Lisa Strifler; Huda Ashoor; Heather MacDonald; Emily Reynen; Reid Robson; Joanne Ho; Carmen Ng; Jesmin Antony; Kelly Mrklas; Brian Hutton; Brenda R Hemmelgarn; David Moher; Sharon E Straus
Journal:  BMC Med       Date:  2015-06-18       Impact factor: 8.775

5.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.